Bristol-Myers Squibb and Pfizer have announced that 19 abstracts (late-breaking, rapid-fire, oral and poster presentations) on apixaban (Eliquis) will be presented at the European Society of Cardiology Congress (ESC; 27–31 August, Rome, Italy).
These new data include post-hoc analyses from ARISTOTLE (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) and retrospective real-world data with analyses from ACROPOLIS (Apixaban experience through real-world population studies).
